Synthesis of Quaternary Carbon Stereogenic Center through Enantioselective Copper-Catalyzed Allylic Substitutions with Vinylaluminum Reagents

Fang Gao, Kevin P. McGrath, Yunmi Lee, Amir H. Hoveyda*

Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts 02467

SUPPORTING INFORMATION, PART 1

General. Infrared (IR) spectra were recorded on a Nicolet 210 spectrophotometer, v_{max} in cm⁻¹. Bands are characterized as broad (br), strong (s), medium (m), and weak (w). ¹H NMR spectra were recorded on a Varian Unity INOVA 400 (400 MHz) spectrometer. Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl₃: δ 7.26 ppm). Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), and coupling constants (Hz). ¹³C NMR spectra were recorded on a Varian Unity INOVA 400 (100 MHz) spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl₃: δ 77.16 ppm). High-resolution mass spectrometry was performed on a Micromass LCT ESI-MS (positive mode) at the Mass Spectrometry Facility, Boston College. Enantiomer ratios were determined by analytical liquid chromatography (HPLC) on a Shimadzu chromatograph (Chiral Technologies Chiralpak AS (4.6 x 250 mm), Chiral Technologies Chiralcel OD (4.6 x 250 mm), Chiral Technologies Chiralcel OD-R (4.6 x 250 mm), Chiral Technologies Chiralcel OJ-H (4.6 x 250 mm), or Chiral Technologies Chiralcel OD-H (4.6 x 250 mm)) in comparison with authentic racemic materials. Optical rotations were measured on a Rudolph Research Analytical Autopol IV Polarimeter.

Unless otherwise noted, all reactions were carried out with distilled and degassed solvents under an atmosphere of dry N_2 in oven- (135 °C) or flame-dried glassware with standard dry box or vacuum-line techniques. All work-up and purification procedures were carried out with reagent grade solvents (purchased from Fisher Inc.) in air.

v Reagents and Ligands:

3-(*tert*-**Butoxy**)**prop-1-yne:** Purchased from Acros and used after distillation from CaH₂ under N₂.

Chlorodiethylphosphate: Purchased from Aldrich and used as received.

5-Chloropent-1-yne: Purchased from Aldrich and used after distillation from CaH₂ under N₂.

Copper (II) chloride dihydrate: Purchased from Aldrich and used without further purification.

Di(iso-butyl)aluminum hydride (dibal-H, neat): Purchased from Aldrich and used as received.

4-Dimethylaminopyridine: Purchased from Advanced Chem Tech used as received.

3,3-Dimethylbut-1-yne: Purchased from Aldrich and used after distillation from CaH₂ under N₂.

1-Ethynylcyclohex-1-ene: Purchased from Aldrich and used after distillation from CaH₂ under vacuum.

1-Ethynyl-4-methoxybenzene: Purchased from Aldrich and used after distillation from CaH₂ under vacuum.

1-Ethynyl-2-methylbenzene: Purchased from Aldrich and used after distillation from CaH₂ under vacuum.

1-Ethynyl-4-(trifluoromethyl)benzene: Purchased from Aldrich and used after distillation from CaH₂ under vacuum.

1-Octyne: Purchased from Aldrich and used after distillation from CaH₂ under N₂.

Phenylacetylene: Purchased from Aldrich and used after distillation from CaH₂ under vaccum.

Tetrahydrofuran: Distilled under N₂ from sodium benzophenone ketyl.

Triethylamine: Purchased from Aldrich and distilled from CaH₂ under N₂.

Dichloromethane, diethyl ether, and hexanes: Purified by being passed through two alumina columns under a positive pressure of dry argon with a modified Advanced ChemTech purification system.

Alkyl-substituted vinylaluminum reagents: Prepared according to a known literature procedure.¹

Chiral NHC-Ag Complex 1a: Prepared based on a previously reported procedure.²

Chiral NHC-Ag Complex 1b: Prepared based on a previously reported procedure.³

Chiral NHC-Ag Complex 1c: Prepared based on a previously reported procedure.⁴

Preparation of trisubstituted allylic phosphate substrates: First, the requisite allylic alcohols were synthesized from the corresponding ketones by a two-step Horner-Wadsworth-Emmons olefination⁵/dibal–H reduction sequence.⁶ Subsequently, allylic alcohols were converted to the corresponding allylic phosphates based on established methods.⁷ Physical attributes of compounds, which have not been reported in the past, are presented below.

⁽¹⁾ Negishi, E.; Takahashi, T.; Baba, S. Org. Synth. Coll. 1993, 8, 295–297.

⁽²⁾ Brown, M. K.; May, T. L.; Baxter, C. A.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2007, 46, 1097–1100.

⁽³⁾ Lee, Y.; Akiyama, K.; Gillingham, D. G.; Brown, M. K.; Hoveyda, A. H.; J. Am. Chem. Soc. 2008, 130, 446–447.

⁽⁴⁾ Akiyama, K.; Gao, F.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2010, 49, 419-423.

⁽⁵⁾ Nestl, B. M.; Glueck, S. M.; Hall, M.; Kroutil, W.; Stuermer, R.; Hauer, B.; Faber, K. Eur. J. Org. Chem. 2006, 71, 4573–4577.

⁽⁶⁾ Clive, D. L. J.; Stoffman, E. J. L. Chem. Commum. 2007, 21, 2151–2153.

⁽⁷⁾ Luchaco-Cullis, C. A.; Mizutani, H.; Murphy, K. E.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2001, 40, 1456–1460.

(*E*)-Diethyl (3-phenylbut-2-en-1-yl) phosphate. IR (neat): 2982 (w), 2908 (w), 1495 (w), 1478 (w), 1445 (w), 1391 (w), 1261 (m), 1165 (w), 1125 (w), 1100 (w), 1062 (w), 1004 (s), 969 (s), 879 (w), 821 (m), 758 (m), 696 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.42–7.39 (2H, m), 7.36–7.32 (2H, m), 7.30–7.28 (1H, m), 5.95 (1H, dt, *J* = 6.8, 1.2 Hz), 4.77 (2H, dd, *J* = 8.0, 7.6 Hz), 4.13 (4H, dq, *J* = 7.2, 1.2 Hz), 2.12 (3H, s), 1.36-1.32 (6H, m); ¹³C NMR (100 MHz, CDCl₃): δ 142.5, 140.5, 128.5, 127.8, 126.0, 122.0 (d, *J* = 6.7 Hz), 64.5 (d, *J* = 5.2 Hz), 63.9 (d, *J* = 6.0 Hz), 16.35 (d, *J* = 3.0 Hz), 16.27; HRMS (ESI+): Calcd for C₁₄H₂₂O₅P₁ [M+OH]⁺: 301.1205, Found: 301.1207.

(*E*)-Diethyl (3-(*o*-tolyl)but-2-en-1-yl) phosphate. IR (neat): 2982 (w), 2931 (w), 1486 (w), 1445 (w), 1381 (w), 1263 (w), 1263 (m), 1166 (w), 1103 (w), 1029 (s), 1009 (s), 977 (s), 881 (w), 827 (w), 761 (w), 729 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.28–7.22 (3H, m), 7.17–7.15 (1H, m), 5.63 (1H, dt, *J* = 6.8, 1.2 Hz), 4.84 (2H, dd, *J* = 8.0, 7.6 Hz), 4.27–4.19 (4H, m), 2.37 (3H, s), 2.10 (3H, s), 1.47–1.43 (6H, m); ¹³C NMR (100 MHz, CDCl₃), δ 144.4, 142.5, 134.8, 130.5, 128.1, 127.4, 126.0, 124.0 (d, *J* = 6.7 Hz), 64.3 (d, *J* = 6.0 Hz), 64.0 (d, *J* = 5.9 Hz), 20.0, 18.7, 16.5 (d, *J* = 6.7 Hz); HRMS (ESI+): Calcd for C₁₅H₂₄O₅P₁ [M+OH]⁺: 315.1361, Found: 315.1370.

(*E*)-3-(2-Bromophenyl)but-2-enyl diethyl phosphate. IR (neat): 2983 (w), 2905 (w), 1468 (w), 1426 (w), 1378 (w), 1270 (m), 1166 (w), 1026 (s), 979 (s), 887 (w), 823 (w), 758 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.56–7.53 (1H, m), 7.29–7.24 (1H, m), 7.17–7.11 (2H, m), 5.59 (1H, dt, *J* = 5.2, 1.2 Hz), 4.74 (2H, dd, *J* = 6.8, 0.8 Hz), 4.14 (4H dq, *J* = 7.2, 0.8 Hz), 2.05–2.04 (3H, m), 1.37–1.34 (6H, m); ¹³C NMR (100 MHz, CDCl₃): δ 145.1, 141.9, 132.9, 129.8, 128.8, 127.5, 125.2 (d, *J* = 6.7 Hz), 121.8, 63.9 (d, *J* = 6.7 Hz), 18.1, 16.3 (d, *J* = 6.7 Hz); HRMS (ESI+): Calcd for C₁₄H₂₁Br₁O₅P₁ [M+OH]⁺: 379.0310, Found: 379.0332.

(*E*)-Diethyl (3-(4-nitrophenyl)but-2-en-1-yl) phosphate. IR (neat): 2984 (w), 2911 (w), 1595 (w), 1515 (m), 1444 (w), 1391 (w), 1369 (w), 1343 (s), 1263 (m), 1165 (w), 1106 (w), 1062 (w), 1005 (s), 974 (s), 853 (s), 818 (m), 747 (m), 695 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 8.21–8.17 (2H, m), 7.56–7.52 (2H, m), 6.07 (1H, dt, J = 6.4, 1.2 Hz), 4.78 (2H, dd, J = 6.4, 0.8 Hz), 4.18–4.10 (4H, m), 2.14–2.13 (3H, m), 1.37–1.33 (6H, m); ¹³C NMR (100 MHz, CDCl₃): δ 148.9, 147.3, 138.2, 126.8, 125.9 (d, J = 6.7 Hz), 123.8, 64.1 (d, J = 4.5 Hz), 64.1 (d, J = 5.2 Hz), 16.3 (d, J = 4.5 Hz), 16.3 (d, J = 2.2 Hz); HRMS (ESI+): Calcd for C₁₄H₂₄N₂O₆P [M+NH₄]⁺: 347.1372, Found: 347.1379.

(*E*)-Diethyl (3-(4-(trifluoromethyl)phenyl)but-2-en-1-yl) phosphate. IR (neat): 2986 (w), 2934 (w), 2910 (w), 1616 (w), 1445 (w), 1411 (w), 1394 (w), 1324 (s), 1265 (m), 1164 (m), 1115 (s), 1059 (m), 1006 (s), 975 (s), 847 (m), 819 (m), 749 (w), 724 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.60–7.57 (2H, m), 7.50–7.48 (2H, m), 6.00 (1H, dt, *J* = 5.6, 1.6 Hz), 4.79–4.75 (2H, m), 4.17–4.10 (4H, m), 2.12 (3H, s), 1.37–1.32 (6H, m); ¹³C NMR (100 MHz, CDCl₃):

δ 146.0, 139.1, 129.7 (q, *J* = 32.0 Hz), 128.8 (q, *J* = 82.1 Hz), 126.3, 125.4 (q, *J* = 3.8 Hz), 124.1 (d, *J* = 6.7 Hz), 64.2 (d, *J* = 5.3 Hz), 64.0 (d, *J* = 5.9 Hz), 17.8, 16.3 (d, *J* = 6.7 Hz); HRMS (ESI+): Calcd for C₁₅H₂₁F₃O₅P₁ [M+OH]⁺: 369.1079, Found: 369.1084.

(*E*)-3-Cyclohexylbut-2-enyl diethyl phosphate. IR (neat): 2982 (w), 2925 (m), 2853 (w), 1663 (w), 1448 (w), 1392 (w), 1369 (w), 1261 (m), 1166 (w), 1098 (w), 1069 (w), 1024 (s), 1001 (s), 972 (s), 881 (w), 852 (w), 830 (w), 801 (m), 747 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 5.37 (1H, ddt, J = 6.8, 2.4, 1.2 Hz), 4.57 (2H, t, J = 7.6 Hz), 4.14–4.06 (4H, m), 1.87 (1H, t, J = 11.6 Hz), 1.77–1.69 (5H, m), 1.67 (3H, s), 1.35–1.30 (6H, m), 1.28–1.11 (6H, m); ¹³C NMR (100 MHz, CDCl₃): δ 147.6, 117.4 (d, J = 6.7 Hz), 64.4 (d, J = 5.9 Hz), 63.7 (d, J = 5.2 Hz), 47.3, 31.7, 26.7, 26.4, 16.3 (d, J = 6.7 Hz), 15.0; HRMS (ESI+): Calcd for C₁₄H₂₈O₅P₁ [M+OH]⁺: 307.1674, Found: 307.1681.

(*E*)-3, 7-Dimethylocta-2, 6-dienyl diethyl phosphate (10, Scheme 4). IR (neat): 2981 (w), 2912 (w), 1669 (w), 1444 (w), 1383 (w), 1261 (m), 1166 (w), 1100 (w), 1027 (s), 972 (s), 886 (w), 818 (m), 801 (m), 746 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 5.41–5.38 (1H, m), 5.10–5.06 (1H, m), 4.56 (2H, t, *J* = 7.6 Hz), 4.14–4.07 (4H, m), 2.13–2.02 (4H, m), 1.69 (6H, d, *J* = 10.0 Hz), 1.60 (3H, s), 1.35–1.31 (6H, m); ¹³C NMR (100 MHz, CDCl₃): δ 142.7, 132.0, 123.8, 119.1 (d, *J* = 6.7 Hz), 64.2 (d, *J* = 5.2 Hz), 63.7 (d, *J* = 5.9 Hz), 39.6, 26.4, 25.8, 17.8, 16.6, 16.3 (d, *J* = 6.7 Hz); HRMS (ESI+): Calcd for C₁₄H₂₈O₅P₁ [M+OH]⁺: 307.1674, Found: 307.1673.

(*E*)-*tert*-Butyl 4-((diethoxyphosphoryl)oxy)-2-methylbut-2-enoate. IR (neat): 2980 (w), 2934 (w), 1708 (m), 1657 (w), 1479 (w), 1457 (w), 1392 (w), 1368 (w), 1333 (w), 1252 (m), 1171 (w), 1134 (m), 1100 (w), 1017 (s), 889 (w), 848 (w), 819 (w), 730 (w), 670 (w), 511 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 6.66–6.63 (1H, m), 4.68–4.63 (2H, m), 4.13–4.05 (4H, m), 1.78 (3H, s), 1.44 (9H, s), 1.33–1.28 (6H, m); ¹³C NMR (100 MHz, CDCl₃): δ 166.4, 134.0 (d, *J* = 7.5 Hz), 132.2, 80.9, 64.0 (d, *J* = 6.0 Hz), 63.9 (d, *J* = 5.2 Hz), 28.1, 16.2 (d, *J* = 6.7 Hz), 12.9; HRMS (ESI+): Calcd for C₁₃H₂₆O₆P₁ [M+H]⁺: 309.1467, Found: 309.1453.

v General Procedure for Cu-catalyzed Enantioselective Allylic Substitutions with Alkylsubstituted Vinylaluminum Reagents (Table 1 and Scheme 3): A 13 x 100 mm test tube equipped with a stir bar is charged with NHC–Ag complex 1a (1.2 mg, 0.0010 mmol) in an N₂filled glovebox. The vessel is sealed with a septum and removed from the glovebox. Tetrahydrofuran (1.0 mL) and a solution of CuCl₂•2H₂O (0.02M in thf, 100 μ L, 0.002 mmol) are added to the test tube at 22 °C. The resulting blue solution is allowed to cool to -78 °C (dry ice/acetone bath), followed by the addition of the vinylaluminum reagent (1.0 M in hexanes, 300 μ L, 0.30 mmol) and a solution of (*E*)-diethyl (3-phenylbut-2-en-1-yl) phosphate (56.9 mg, 0.200 mmol) in thf (1.0 mL). The mixture is allowed to warm to -15 °C and sit in a freezer for 3 h, after which time, the reaction is quenched by the addition of a saturated aqueous solution of Rochelle's salt (2.0 mL) at -78 °C and the resulting mixture is allowed to warm to 22 °C and stir for one hour. The layers are separated, and the aqueous layer is washed with Et₂O (2.0 mL x 3). The combined organic layers are passed through a short plug of MgSO₄, and concentrated under reduced pressure. The resulting yellow oil is purified by silica gel chromatography to give the product as colorless oil (39.8 mg, 0.164 mmol, 82% yield). (*R,E*)-(3-Methylundeca-1,4-dien-3-yl)benzene (entry 1, Table 1). IR (neat): 3083 (w), 2957 (m), 2925 (s), 2871 (m), 2854 (s), 1633 (w), 1599 (w), 1492 (m), 1460 (m), 1445 (m), 975 (m), 914 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.36–7.29 (4H, m), 7.22-7.18 (1H, m), 6.09 (1H, dd, *J* = 17.6, 10.8 Hz), 5.67 (1H, dt, *J* = 15.6, 1.6 Hz), 5.43 (1H, dt, *J* = 15.6, 6.8 Hz), 5.12 (1H, dd, *J* = 10.8, 1.6 Hz), 5.02 (1H, dd, *J* = 17.2, 1.6 Hz), 2.09 (2H, dtd, *J* = 6.8, 6.8, 1.2 Hz), 1.49 (3H, s), 1.42–1.27 (8H, m), 0.90 (3H, t, *J* = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 147.2, 146.0, 137.0, 129.1, 128.2, 127.3, 126.1, 112.4, 47.6, 32.9, 31.9, 29.7, 29.1, 25.9, 22.9, 14.3; HRMS (ESI+): Calcd for C₁₈H₂₇ [M+H]⁺: 243.2113, Found: 243.2118. Elemental Analysis: Calcd for C₁₈H₂₆: C, 89.19; H, 10.81; Found: C, 89.35; H, 10.60. Optical Rotation: [α]_D²⁰ –5.31 (*c* 1.50, CHCl₃) for an enantiomerically enriched sample of 94.5:5.5 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (94.3:5.7 er shown; Chiralcel OD column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*E*)-1-Bromo-2-(3-methylundeca-1,4-dien-3-yl)benzene (entry 2, Table 1). IR (neat): 2956 (w), 2923 (m), 2853 (w), 1463 (m), 1431 (w), 1267 (w), 1019 (m), 987 (w), 966 (m), 944 (m), 754 (s), 734 (m), 724 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.57 (1H, dd, *J* = 8.0, 1.2 Hz), 7.46 (1H, dd, *J* = 8.0, 1.6 Hz), 7.25 (1H, dt, *J* = 8.0, 0.8 Hz), 7.06 (1H, dq, *J* = 7.2, 0.8 Hz), 6.19 (1H, dd, *J* = 17.2, 10.8 Hz), 5.74 (1H, dt, *J* = 15.6, 0.8 Hz), 5.30 (1H, dt, *J* = 15.6, 6.8 Hz), 5.10 (1H, dt, *J* = 10.8, 0.9 Hz), 4.93 (1H, dd, *J* = 17.6, 0.8 Hz), 2.07 (2H, dtd, *J* = 7.2, 7.2, 1.6 Hz), 1.62 (3H, s), 1.39–1.26 (8H, m), 0.88 (3H, t, *J* = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 145.8, 145.5, 136.4, 135.6, 129.8, 129.5, 128.0, 127.1, 124.0, 112.8, 48.8, 32.9, 31.9, 29.5, 29.1, 26.3, 22.8, 14.3. Elemental Analysis: Calcd for C₁₈H₂₅Br₁: C, 67.29; H, 7.84; Found: C, 67.34; H,

7.84. Optical Rotation: $[\alpha]_D^{20}$ –9.71 (*c* = 1.12, CHCl₃) for an enantiomerically enriched sample of 96.5:3.5 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (97.9:2.1 er shown; Chiralcel OD column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*E*)-1-(3-Methylundeca-1,4-dien-3-yl)-2-(trifluoromethyl)benzene (entry 3, Table 1). IR (neat): 2957 (w), 2925 (w), 2855 (w), 1488 (w), 1304 (s), 1268 (m), 1166 (s), 1129 (s), 1034 (s), 912 (m), 765 (s) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.70 (1H, dd, J = 8.0, 1.6 Hz), 7.63 (1H, d, J = 8.0 Hz), 7.46 (1H, dq, J = 8.0, 0.8 Hz), 7.35–7.31 (1H, m), 6.14 (1H, ddd, J = 17.6, 10.8, 0.8 Hz), 5.72 (1H, dd, J = 15.6, 0.8 Hz), 5.28 (1H, dt, J = 15.6, 6.8 Hz), 5.06 (1H, dd, J = 10.8, 0.8 Hz), 4.88 (1H, dd, J = 17.2, 0.8 Hz), 2.05 (2H, dtd, J = 6.8, 6.8, 1.2 Hz), 1.57 (3H, s), 1.38–1.26 (8H, m), 0.89 (3H, t, J = 7.2 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 146.5, 145.9, 137.3, 131.4, 130.6, 129.2 (q, J = 30.7 Hz), 128.6, 128.6, 128.5, 124.7 (q, J = 272.8 Hz), 111.7, 48.7, 32.9, 31.9, 29.4, 29.1, 27.4, 22.8, 14.3; HRMS (ESI+): Calcd for C₁₉H₂₆F₃ [M+H]⁺: 311.1987, Found: 311.1979. Optical Rotation: [α]_D²⁰ –13.3 (c = 1.00, CHCl₃) for an enantiomerically enriched sample of 98:2 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (98.0:2.0 er shown; Chiralcel OD column, 99.5/0.5 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*E*)-1-(3-Methylundeca-1,4-dien-3-yl)-2-nitrobenzene (entry 4, Table 1). IR (neat): 2956 (w), 2925 (m), 2855 (w), 1531 (s), 1367 (m), 974 (w), 916 (w), 850 (w), 751 (s), 650 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.53 (1H, dd, J = 7.2, 1.2 Hz), 7.47–7.39 (2H, m), 7.32 (1H, dt, J = 7.2, 1.2 Hz), 6.01 (1H, dd, J = 17.2, 10.6 Hz), 5.58 (1H, d, J = 16.4 Hz), 5.44 (1H, dt, J = 16.4, 6.0 Hz), 5.13 (1H, d, J = 10.6 Hz), 5.02 (1H, d, J = 17.6 Hz), 2.01 (2H, dt, J = 6.0, 6.0 Hz), 1.62 (3H, s), 1.40–1.24 (8H, m), 0.88 (3H, t, J = 6.4 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 151.3, 143.8, 139.3, 134.3, 131.2, 130.5, 130.2, 127.5, 124.4, 112.9, 47.4, 32.8, 31.9, 29.3, 29.2, 25.7, 22.9, 14.3; HRMS (ESI+): Calcd for C₁₈H₂₆N₁O₂ [M+H]⁺: 288.1964, Found: 288.1961. Elemental Analysis: Anal Calcd for C₁₈H₂₅N₁O₂: C, 75.22; H, 8.77; N, 4.87; Found: C, 75.49; H, 9.04; N, 5.05. Optical Rotation: [α]_D²⁰ +0.71 (*c* 1.00, CHCl₃) for an enantiomerically enriched sample of 97.5:2.5 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (97.6:2.4 er shown; Chiralcel OD column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 254 nm).



|--|

(*R*,*E*)-1-Methoxy-2-(3-methylundeca-1,4-dien-3-yl)benzene (entry 5, Table 1). IR (neat): 2956 (w), 2924 (m), 2853 (w), 1487 (m), 1461 (m), 1434 (m), 1241 (s), 1031 (m), 967 (w), 909 (m), 748 (s), 670 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.27 (1H, dd, *J* = 7.6, 1.6 Hz), 7.21 (1H, dt, *J* = 7.6, 1.6 Hz), 6.91–6.86 (2H, m), 6.18 (1H, dd, *J* = 17.2, 10.4 Hz), 5.73 (1H, dt, *J* = 15.6, 1.2 Hz), 5.32 (1H, dt, *J* = 15.6, 6.0 Hz), 5.01 (1H, dd, *J* = 10.4, 1.6 Hz,), 4.91 (1H, dd, *J* = 17.2, 1.2 Hz), 3.76 (3H, s), 2.04 (2H, dt, *J* = 6.0, 6.0 Hz), 1.53 (3H, s), 1.35–1.27 (8H, m), 0.88 (3H, t, *J* = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 158.3, 146.3, 137.1, 135.7, 128.3, 127.9, 127.8, 120.5, 112.3, 111.2, 55.3, 46.5, 33.0, 32.0, 29.9, 29.1, 24.8, 22.9, 14.3; HRMS (ESI+): Calcd for C₁₉H₂₉O₁ [M+H]⁺: 273.2218, Found: 273.2219. Optical Rotation: $[\alpha]_D^{20}$ –3.36 (*c* 1.00, CHCl₃) for an enantiomerically enriched sample of 98:2 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (97.9:2.1 er shown; Chiralcel OD-R column, 99/1 hexanes/*i*-PrOH, 0.5 mL/min, 220 nm).



(*R*,*E*)-1-Methyl-2-(3-methylundeca-1,4-dien-3-yl)benzene (entry 6, Table 1). IR (neat): 3014 (m), 2957 (m), 2853 (m), 1631 (w), 1485 (w), 1456 (m), 972 (m), 910 (m), 759 (s), 728 (s) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.40–7.37 (1H, m), 7.17–7.12 (3H, m), 6.14 (1H, dd, *J* = 17.2, 10.4 Hz), 5.73 (1H, dt, *J* = 15.6, 1.6 Hz), 5.28 (1H, dt, *J* = 15.6, 6.8 Hz), 5.06 (1H, dd, *J* = 10.4, 1.2 Hz), 4.90 (1H, dd, *J* = 17.6, 1.2 Hz), 2.33 (3H, s), 2.05 (2H, dtd, *J* = 6.8, 6.8, 1.6 Hz), 1.53 (3H, s), 1.38–1.27 (8H, m), 0.89 (3H, t, *J* = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 146.3, 144.5, 137.6, 137.2, 132.4, 128.6, 127.6, 126.5, 125.6, 111.9, 48.1, 33.0, 31.9, 29.6, 29.1, 27.5, 22.9, 22.8, 14.3; HRMS (ESI+): Calcd for C₁₉H₂₉ [M+H]⁺: 257.2269, Found: 257.2274. Optical Rotation: $[\alpha]_D^{20}$ –7.58 (*c* 1.26, CHCl₃) for an enantiomerically enriched sample of 96.5:3.5 er.

Enantiomeric purity is determined by HPLC analysis in comparison with authentic racemic material (96.5:3.5 er shown; Chiralpak OD-H column, 99.8/0.2 hexanes/*i*-PrOH, 0.3 mL/min, 220 nm).



(*R*,*E*)-1-(3-Methylundeca-1,4-dien-3-yl)-4-nitrobenzene (entry 7, Table 1). IR (neat): 2956 (w), 2926 (m), 2855 (w), 1597 (w), 1518 (s), 1492 (w), 1459 (w), 1345 (s), 1216 (w), 1111 (w), 1014 (w), 1000 (w), 976 (w), 920 (w), 852 (m), 755 (s), 701 (m), 668 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.14 (2H, d, *J* = 6.8 Hz), 7.48 (2H, d, *J* = 9.2 Hz), 6.03 (1H, dd, *J* = 17.6, 10.6 Hz), 5.62 (1H, d, *J* = 15.6 Hz), 5.43 (1H, dt, *J* = 16.0, 6.8 Hz), 5.18 (1H, d, *J* = 10.6 Hz), 5.03 (1H, d, *J* = 17.6 Hz), 2.08 (2H, dt, *J* = 7.2, 7.2 Hz), 1.50 (3H, s), 1.43–1.27 (8H, m), 0.89 (3H, t, *J* = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 155.0, 146.5, 144.6, 135.7, 130.7, 128.4, 123.5, 113.8, 48.0, 32.9, 31.9, 29.6, 29.1, 26.0, 22.9, 14.3; HRMS (ESI+): Calcd for C₁₈H₂₆N₁O₂ [M+H]⁺: 288.1964, Found: 288.1949. Elemental Analysis: Anal Calcd for C₁₈H₂₅N₁O₂: C, 75.22; H, 8.77; N, 4.87; Found: C, 75.49; H, 8.90; N, 4.98. Optical Rotation: [α]_D²⁰ –7.54 (*c* = 1.00, CHCl₃) for an enantiomerically enriched sample of 94.5:5.5 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (94.4:5.6 er shown; Chiralcel OD-R column, 98/2 hexanes/*i*-PrOH, 1.0 mL/min, 240 nm).



2	28.44	49.7	2	28.47	5.6
---	-------	------	---	-------	-----

(*S*,*E*)-(**3**-Methylundeca-1,4-dien-3-yl)cyclohexane (entry 8, Table 1). IR (neat): 2922 (s), 2852 (s), 1450 (m), 1000 (w), 973 (m), 910 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 5.82 (1H, dd, J = 17.6, 10.8 Hz), 5.40 (1H, dt, J = 15.6, 1.2 Hz), 5.28 (1H, dt, J = 15.6, 6.4 Hz), 4.97 (1H, dd, J = 10.8, 1.6 Hz), 4.89 (1H, dd, J = 17.6, 1.6 Hz), 2.01 (2H, dt, J = 6.4, 6.4 Hz), 1.75-1.69 (4H, m), 1.64–1.61 (1H, m), 1.36–1.19 (8H, m), 1.18–1.05 (4H, m), 1.01 (3H, s), 0.94–0.86 (5H, m); ¹³C NMR (100 MHz, CDCl₃): δ 146.4, 137.0, 128.3, 111.6, 47.4, 45.3, 33.2, 31.9, 29.9, 29.2, 28.0, 27.4, 27.0, 22.9, 20.2, 14.3; HRMS (ESI+): Calcd for C₁₈H₃₃ [M+H]⁺: 249.2582, Found: 249.2591. Elemental Analysis: Anal Calcd for C₁₈H₃₂: C, 87.02; H, 12.98; Found: C, 87.30; H, 13.26. Optical Rotation: $[\alpha]_D^{20}$ –16.3 (*c* 1.00, CHCl₃) for an enantiomerically enriched sample of 93:7 er.

Site-selective hydroboration (9-BBN)/oxidation (H_2O_2) of the terminal alkene of the EAS product and generation of the derived Mosher ester, according to published procedures,⁸ was performed first. Enantiomeric purity was determined by analysis of the ¹H NMR spectrum in comparison with that of authentic Mosher ester of racemic primary alcohol.⁹ (See ¹H NMR spectra for racemic and enantiomerically enriched Mosher esters in the Appendix, 94.9:5.1 er shown).



(*R*,*E*)-2,6-Dimethyl-6-vinyltetradeca-2,7-diene (entry 9, Table 1). IR (neat): 2960 (m), 2923 (s), 2854 (m), 1634 (w), 1455 (m), 1376 (w), 1459 (w), 972 (s), 911 (s), 837 (w), 724 (w), 681 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 5.80 (1H, dd, *J* = 17.6, 10.8 Hz), 5.40–5.29 (2H, m), 5.09 (1H, tt, *J* = 7.2, 1.6 Hz), 4.97–4.91 (2H, m), 2.03–1.98 (2H, m), 1.89 (2H, dt, *J* = 6.8, 6.8 Hz), 1.67 (3H, s), 1.58 (3H, s), 1.38–1.27 (10H, m), 1.07 (3H, s), 0.88 (3H, t, *J* = 6.8 Hz); ¹³C

⁽⁸⁾ Fujii, M.; Fukumura, M.; Hori, Y.; Hirai, Y.; Akita, H.; Nakamura, K.; Toriizukaa, K.; Idaa, Y. *Tetrahedron;* Asymmetry **2006**, *17*, 2292–2298.

⁽⁹⁾ Dale, J. A.; Dull, D. L.; Mosher, H. S. J. Org. Chem. 1969, 34, 2543-2549.

NMR (100 MHz, CDCl₃): δ 146.8, 137.3, 131.4, 128.1, 125.0, 111.3, 42.5, 41.9, 35.2, 34.2, 32.1, 31.3, 28.0, 23.7, 23.6, 23.0, 17.9, 14.6; HRMS (ESI+): Calcd for C₁₈H₃₃ [M+H]⁺: 249.2582, Found: 249.2588. Optical Rotation: $[\alpha]_D^{20}$ –8.37 (*c* 1.48, CHCl₃) for an enantiomerically enriched sample of 92.5:7.5 er.

Site-selective hydroboration (9-BBN)/oxidation (H_2O_2) of the terminal alkene of the EAS product and generation of the derived Mosher ester, according to published procedures,⁹ was performed first. Enantiomeric purity was determined by analysis of the ¹H NMR spectrum in comparison with that of authentic Mosher ester of racemic primary alcohol.⁸ (See the ¹H NMR spectra for racemic and enantiomerically enriched Mosher esters in the Appendix, 92.2:7.8 er shown).



(*R*,*E*)-*tert*-Butyl 2-methyl-2-vinyldec-3-enoate (entry 10, Table 1). IR (neat): 2958 (w), 2926 (m), 2855 (w), 1726 (s), 1456 (w), 1409 (m), 1250 (s), 1160 (s), 1123 (s), 971 (m), 915 (m), 850 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 6.04 (1H, dd, *J* = 18.0, 10.0 Hz), 5.60 (1H, dt, *J* = 16.0, 0.8 Hz), 5.47 (1H, dt, *J* = 15.6, 6.8 Hz), 5.08–5.04 (2H, m), 2.03 (2H, dtd, *J* = 7.6, 7.6, 0.8 Hz), 1.42 (9H, s), 1.37–1.24 (8H, m), 1.32 (3H, s), 0.87 (3H, t, *J* = 6.8 H); ¹³C NMR (100 MHz, CDCl₃): δ 174.2, 141.7, 132.6, 130.3, 113.4, 80.7, 51.4, 32.8, 31.9, 29.5, 28.9, 28.1, 22.8, 21.6, 14.3; HRMS (ESI+): Calcd for C₁₇H₃₁O₂ [M+H]⁺: 267.2324, Found: 267.2325. Optical Rotation: [α]_D²⁰ –11.4 (*c* 0.91, CHCl₃) for an enantiomerically enriched sample of 90:10 er.

Enantiomeric purity is determined by HPLC analysis in comparison with authentic racemic material (90.1:9.9 er shown; Chiralcel OD-H column, 99.8/0.2 hexanes/*i*-PrOH, 0.3 mL/min, 220 nm).



(*R*,*E*)-Dimethyl(3-methylundeca-1,4-dien-3-yl)(phenyl)silane (entry 11, Table 1). IR (neat): 2956 (w), 2925 (w), 2856 (w), 1724 (w), 1427 (w), 1251 (w), 1117 (w), 1052 (w), 1026 (w), 998 (w), 829 (m), 811 (m), 790 (m), 773 (m), 698 (s) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.49–7.47 (2H, m), 7.39–7.31 (3H, m), 5.93 (1H, dd, *J* = 17.6, 10.8 Hz), 5.54 (1H, dt, *J* = 15.6, 1.2 Hz), 5.16 (1H, dt, *J* = 15.2, 7.2 Hz), 4.92 (1H, dd, *J* = 10.8, 1.2 Hz), 4.75 (1H, dd, *J* = 17.2, 0.8 Hz), 2.03 (2H, dt, *J* = 6.8, 6.8 Hz), 1.36–1.23 (8H, m), 1.11 (3H, s), 0.89 (3H, t, *J* = 6.8 Hz), 0.28 (6H, s); ¹³C NMR (100 MHz, CDCl₃): δ 143.3, 136.8, 135.0, 133.9, 129.2, 127.4, 126.8, 109.9, 36.2, 33.4, 32.0, 30.2, 29.1, 22.9, 17.9, 14.3, –5.8; HRMS (ESI+): Calcd for C₂₀H₃₃Si₁ [M+H]⁺: 301.2352, Found: 301.2348. Optical Rotation: [α]_D²⁰ –3.56 (*c* 0.46, CHCl₃) for an enantiomerically enriched sample of 95.5:4.5 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (95.5:4.5 er shown; Chiralcel OD column, 99.5/0.5 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



Peak#	Ret. Time	Area%	Peak#	Ret. Time	Area%
1	20.12	47.9	1	20.07	95.5
2	22.86	52.1	2	23.00	4.5

(*R*,*E*)-Dimethyl(phenyl)(3,6,6-trimethylhepta-1,4-dien-3-yl)silane (3, Scheme 3). IR (neat): 2956 (m), 1427 (w), 1247 (m), 1113 (m), 976 (m), 894 (m), 810 (s), 772 (s), 734 (s), 698 (s), 473 (m), 404 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.47–7.45 (2H, m), 7.36–7.32 (3H, m), 5.92 (1H, dd, *J* = 17.6, 10.8 Hz), 5.42 (1H, d, *J* = 16.0 Hz), 5.15 (1H, d, *J* = 16.0 Hz), 4.91 (1H, dd, *J* = 10.4, 1.2 Hz), 4.74 (1H, dd, *J* = 17.2, 1.2 Hz), 1.09 (3H, s), 0.98 (9H, s), 0.25 (6H, s); ¹³C NMR (100 MHz, CDCl₃): δ 143.5, 137.4, 136.8, 134.9, 129.2, 128.6, 127.4, 109.8, 35.8, 33.3, 30.2, 17.8, -6.0; HRMS (ESI+): Calcd for C₁₈H₂₉Si₁ [M+H]⁺: 273.2039, Found: 273.2027. Optical Rotation: $[\alpha]_D^{20}$ +10.82 (*c* 3.58, CHCl₃) for an enantiomerically enriched sample of 91:9 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (91.5:8.5 er shown; Chiralcel OD column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*E*)-(9-(*tert*-Butoxy)-3-methylnona-1,4-dien-3-yl)dimethyl(phenyl)silane (4, Scheme 3). IR (neat): 2970 (m), 2927 (m), 2860 (w), 1621 (w), 1427 (w), 1361 (m), 1248 (m), 1198 (m), 1081 (m), 972 (m), 894 (m), 830 (s), 810 (s), 773 (s), 735 (s), 699 (s), 654 (m), 472 (m), 409 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.48–7.46 (2H, m), 7.36–7.32 (3H, m), 5.91 (1H, dd, *J* = 17.2, 10.8 Hz), 5.54 (1H, d, *J* = 15.6 Hz), 5.15 (1H, dt, *J* = 15.6, 7.2 Hz), 4.91 (1H, dd, *J* = 10.8, 1.2 Hz), 4.74 (1H, dd, *J* = 17.2, 1.2 Hz), 3.33 (2H, t, *J* = 7.6 Hz), 2.04 (2H, dt, *J* = 7.2, 7.2 Hz), 1.54–1.49 (2H, m), 1.43–1.39 (2H, m), 1.20 (9H, s), 1.10 (3H, s), 0.26 (6H, s); ¹³C NMR (100 MHz, CDCl₃): δ 143.3, 136.8, 135.0, 134.1, 129.2, 127.5, 126.6, 110.0, 72.6, 61.7, 36.4, 33.3, 30.5, 29.9, 27.8, 26.9, 17.9, –5.8; HRMS (ESI+): Calcd for C₂₂H₃₆O₁Si₁Na₁ [M+Na]⁺: 367.2433,

Found: 367.2420. Optical Rotation: $[\alpha]_D^{20}$ –0.11 (*c* 1.43, CHCl₃) for an enantiomerically enriched sample of 96:4 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (95.8:4.2 er shown; Chiralcel OD column, 99/1 hexanes/*i*-PrOH, 0.2 mL/min, 220 nm).



(*R*,*E*)-(8-Chloro-3-methylocta-1,4-dien-3-yl)dimethyl(phenyl)silane (5, Scheme 3). IR (neat): 2957 (w), 1621 (w), 1427 (w), 1247 (m), 1112 (m), 974 (m), 896 (m), 810 (s), 773 (s), 735 (s), 699 (s), 653 (s), 471 (m), 409 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.47–7.45 (2H, m), 7.37–7.33 (3H, m), 5.91 (1H, dd, *J* = 17.6, 11.2 Hz), 5.61 (1H, d, *J* = 15.2 Hz), 5.06 (1H, dt, *J* = 15.6, 6.4 Hz), 4.92 (1H, dd, *J* = 11.2, 1.2 Hz), 4.75 (1H, dd, *J* = 17.6, 1.2 Hz), 3.49 (2H, t, *J* = 6.8 Hz), 2.18 (2H, dt, *J* = 6.4, 6.4 Hz), 1.80 (2H, q, *J* = 7.2 Hz), 1.10 (3H, s), 0.27 (6H, s); ¹³C NMR (100 MHz, CDCl₃): δ 143.0, 136.6, 135.8, 134.9, 129.3, 127.6, 124.4, 110.2, 44.7, 36.7, 32.7, 30.4, 17.9, -5.8, -5.8; HRMS (ESI+): Calcd for C₁₇H₂₅Cl₁Si₁Na₁ [M+Na]⁺: 315.1312, Found: 315.1319. Optical Rotation: $[\alpha]_D^{20}$ +0.92 (*c* 2.76, CHCl₃) for an enantiomerically enriched sample of 96:4 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (95.9:4.1 er shown; Chiralpak AS column, 99/1 hexanes/*i*-PrOH, 0.5 mL/min, 220 nm).



(*R*,*Z*)-(6-(*tert*-Butoxy)-3-methylhexa-1,4-dien-3-yl)dimethyl(phenyl)silane (6, Scheme 3). IR (neat): 2971 (m), 1363 (m), 1248 (m), 1196 (m), 1111 (m), 1069 (m), 892 (m), 808 (s), 773 (s), 735 (s), 700 (s), 654 (m), 474 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.53–7.51 (2H, m), 7.38– 7.33 (3H, m), 6.04 (1H, dd, *J* = 17.2, 10.4 Hz), 5.47 (1H, d, *J* = 12.4 Hz), 5.40, (1H, dt, *J* = 11.6, 5.6 Hz), 4.97 (1H, d, *J* = 10.8 Hz), 4.81 (1H, dd, *J* = 17.6, 0.8 Hz), 3.87 (1H, dd, *J* = 11.2, 5.6 Hz), 3.77 (1H, ddd, *J* = 12.0, 6.0, 1.2 Hz), 1.25 (3H, s), 1.14 (9H, s), 0.32 (3H, s), 0.31 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 143.6, 136.4, 135.0, 133.9, 129.3, 127.9, 127.6, 110.3, 72.9, 58.8, 37.2, 27.8, 19.2, -5.9; HRMS (ESI+): Calcd for C₁₉H₃₀O₁Si₁Na₁ [M+Na]⁺: 325.1964, Found: 325.1973. Optical Rotation: $[\alpha]_D^{20}$ –26.78 (*c* 1.63, CHCl₃) for an enantiomerically enriched sample of 94.8:5.2 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (94.8:5.2 er shown; Chiralcel OD-H column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



2	15.15	50.6	2	14.89	5.2

(*R*,*E*)-1-Bromo-2-(1-(cyclohex-1-en-1-yl)-3-methylpenta-1,4-dien-3-yl)benzene (7, Scheme 4). IR (neat): 2925 (m), 1463 (m), 1018 (s), 963 (s), 911 (s), 791 (w), 756 (s), 645 (m), 454 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.58 (1H, dd, *J* = 8.0, 1.6 Hz), 7.46 (1H, dd, *J* = 8.0, 1.6 Hz), 7.26 (1H, dt, *J* = 7.6, 1.2 Hz), 7.08 (1H, dt, *J* = 8.0, 1.6 Hz), 6.22 (1H, dd, *J* = 17.2, 10.4 Hz), 5.92 (2H, s), 5.66–5.64 (1H, m), 5.13 (1H, dd, *J* = 10.8, 1.2 Hz), 4.97 (1H, dd, *J* = 17.6, 0.8 Hz), 2.22–2.18 (2H, m), 2.13–2.09 (2H, m), 1.70–1.65 (2H, m), 1.66 (3H, s), 1.63–1.59 (2H, m); ¹³C NMR (100 MHz, CDCl₃): δ 145.9, 145.2, 135.9, 135.6, 132.9, 132.2, 129.7, 128.5, 128.1, 127.2, 124.0, 112.9, 48.7, 26.1, 26.0, 24.8, 22.83, 22.78; HRMS (ESI+): Calcd for C₁₈H₂₂Br₁ [M+H]⁺: 317.0905, Found: 317.0906. Optical Rotation: [α]_D²⁰ –27.4 (*c* 1.29, CHCl₃) for an enantiomerically enriched sample of 97.5:2.5 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (97.4:2.6 er shown; Chiralcel OD column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*E*)-1-Bromo-2-(3-methyl-1-phenylpenta-1,4-dien-3-yl)benzene (8, Scheme 4). IR (neat): 3080 (w), 3057 (w), 3024 (w), 2971 (w), 2918 (w), 2849 (w), 1630 (w), 1597 (w), 1491 (w), 1464 (w), 1427 (w), 1368 (w), 1018 (m), 963 (m), 912 (m), 746 (s), 690 (s), 646 (w), 458 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.61 (1H, dd, J = 8.0, 1.6 Hz), 7.51 (1H, dd, J = 7.6, 1.6 Hz), 7.38 (2H, dd, J = 8.4, 1.2 Hz), 7.32–7.27 (3H, m), 7.21 (1H, tt, J = 6.8, 2.0 Hz), 7.11, (1H, dt, J = 8.0, 2.0 Hz), 6.57 (1H, d, J = 16.0 Hz), 6.33–6.25 (2H, m), 5.19 (1H, dd, J = 10.4, 0.8 Hz), 5.04 (1H, dd, J = 17.6, 1.2 Hz), 1.75 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 145.4, 144.6, 137.9, 137.2, 135.6, 131.7, 129.7, 128.7, 128.5, 128.2, 127.2, 126.3, 123.9, 113.4, 49.0, 26.0; HRMS (ESI+): Calcd for C₁₈H₁₈Br₁ [M+H]⁺: 313.0592, Found: 313.0589. Optical Rotation: [α]_D²⁰-31.12 (*c* 0.91, CHCl₃) for an enantiomerically enriched sample of 98:2 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in

comparison with authentic racemic material (98.2:1.8 er shown; Chiralcel OJ-H column, 95/5 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*Z*)-(1-(4-Methoxyphenyl)-3,7-dimethyl-3-vinylocta-1,6-dien-2-yl)trimethylsilane (11, Scheme 5). IR (neat): 2964 (w), 2929 (w), 2835 (w), 1609 (w), 1505 (s), 1464 (w), 1283 (w), 1244 (s), 1172 (m), 1038 (m), 911 (w), 835 (s), 763 (s), 679 (w), 646 (w), 573 (w), 514 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.20 (1H, s), 7.04 (2H, dd, *J* = 8.8, 1.2 Hz), 6.80 (2H, d, *J* = 8.8 Hz), 5.95 (1H, dd, *J* = 17.6, 10.8 Hz), 5.14–5.09 (1H, m), 5.04–4.97 (2H, m), 3.80 (3H, s), 1.94 (2H, dt, *J* = 8.0, 8.0 Hz), 1.75–1.68 (4H, m), 1.60–1.50 (4H, m), 1.23 (3H, s), -0.09 (9H, s); ¹³C NMR (100 MHz, CDCl₃): δ 158.5, 149.5, 148.2, 141.8, 134.1, 131.3, 129.9, 125.1, 113.2, 112.1, 55.4, 47.7, 39.9, 25.9, 25.7, 23.7, 17.9, 3.9; HRMS (ESI+): Calcd for C₂₂H₃₅O₁Si₁ [M+H]⁺: 343.2457, Found: 343.2457.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (56.2:43.8 er shown; Chiralcel OD column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



1	22.73	49.9	1	22.70	56.2
2	33.89	50.1	2	34.01	43.8

■ General Procedure for Catalytic Hydroalumination of Aryl-substituted Terminal Alkynes with Ni(PPh₃)₂Cl₂ (Table 2, Scheme 6 and 7): Commercial grade bis(triphenylphosphine)nickel dichloride (Ni(PPh₃)₂Cl₂, 19.6 mg, 0.0300 mmol) is placed in an oven-dried 13 x 100 mm test tube equipped with a stir bar. The vessel is sealed with a septum and purged with N₂ for approximately ten minutes. Tetrahydrofuran (thf, 1.0 mL) is added through a syringe, followed by dropwise addition of dibal–H (232 µL, 1.3 mmol) at 22 °C (gas evolution occurs as dibal–H is added). The resulting black solution is allowed to cool to 0 °C (ice bath) before phenylacetylene (110 µL, 1.0 mmol) is added slowly over five minutes (reaction is exothermic). The resulting black solution is allowed to warm to 22 °C and stir for additional two hours and used without further purification.

■ General Procedure for NHC–Cu-catalyzed Enantioselective Allylic Substitutions with Aryl-substituted Vinylaluminum Reagents (Table 2 and Scheme 6 and 7): A 13 x 100 mm test tube equipped with a stir bar is charged with NHC-Ag complex 1c (2.3 mg, 0.0020 mmol) in an N₂-filled glovebox. The vessel is sealed with a septum and removed from the glovebox. Tetrahydrofuran (1.0 mL) and a solution of CuCl₂•2H₂O (0.02M in thf, 200 µL, 0.0040 mmol) are added to the test tube at 22 °C. The resulting blue solution is allowed to cool to -78 °C (dry ice/acetone), followed by the addition of the aryl-substituted vinylaluminum reagent (0.745 M in thf, 403 µL, 0.300 mmol) and a solution of (E)-diethyl (3-phenylbut-2-en-1-yl) phosphate (56.9 mg, 0.200 mmol) in thf (1.0 mL). The mixture is allowed to warm to -15 °C and sit in a freezer for three hours, after which time, the reaction is guenched by addition of a saturated aqueous solution of Rochelle's salt (2.0 mL) at -78 °C and the resulting mixture is allowed to warm to 22 °C and stir for one hour. The layers are separated, and the aqueous layer is washed with Et₂O (2.0 mL x 3). The combined organic layers are passed through a short plug of MgSO₄, and concentrated under reduced pressure. The resulting yellow oil is purified by silica gel chromatography to give the product as colorless oil (36.6 mg, 0.156 mmol, 78% yield). (R,E)-(3-Methylpenta-1,4-diene-1,3-diyl)dibenzene (entry 1, Table 2). IR (neat): 3082 (w), 3057 (w), 3025 (w), 2973 (w), 2917 (w), 2872 (w), 2849 (w), 1633 (w), 1598 (w), 1492 (m), 1445 (m), 1408 (w), 1368 (w), 1072 (w), 1029 (w), 971 (m), 916 (m), 748 (s), 694 (s) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.34–7.29 (4H, m), 7.28–7.22 (4H, m), 7.18–7.13 (2H, m), 6.39 (1H, d, J = 16.0 Hz), 6.29 (1H, d, J = 16.0 Hz), 6.09 (1H, dd, J = 17.6, 10.4 Hz), 5.11 (1H, dd, J = 10.8, 1.2 Hz), 5.00 (1H, dd, J = 17.6, 1.2 Hz), 1.55 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 146.5, 145.2, 137.7, 137.3, 131.7, 128.7, 128.4, 128.2, 127.4, 127.3, 126.4, 113.2, 48.0, 25.7; HRMS (ESI+): Calcd for $C_{18}H_{19} [M+H]^+$: 235.1487, Found: 235.1476. Optical Rotation: $[\alpha]_D^{20}$ +33.80 (*c* 2.02, CHCl₃) for an enantiomerically enriched sample of 96:4 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (95.6:4.4 er shown; Chiralpak AS column, 99/1 hexanes/*i*-PrOH, 0.5 mL/min, 220 nm).



(*R*,*E*)-1-Methyl-2-(3-methyl-3-phenylpenta-1,4-dien-1-yl)benzene (entry 2, Table 2). Spectra were recorded with samples containing 12% alkynyl adduct. IR (neat): 3059 (w), 3021 (w), 2958 (m), 2924 (m), 2854 (m), 1634 (w), 1600 (w), 1490 (m), 1459 (m), 1378 (w), 1029 (w), 951 (m), 916 (m), 747 (s), 698 (s) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.48–7.46 (1H, m), 7.42–7.38 (2H, m), 7.37–7.32 (2H, m), 7.26–7.21 (2H, m), 7.19–7.14 (2H, m), 6.59 (1H, d, *J* = 16.0 Hz), 6.33 (1H, d, *J* = 16.0 Hz), 6.20 (1H, dd, *J* = 17.2, 10.4 Hz), 5.21 (1H, dd, *J* = 10.8, 1.2 Hz), 5.10 (1H, dd, *J* = 17.6, 1.2 Hz), 2.33 (3H, s), 1.64 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 146.6, 145.3, 138.8, 137.0, 135.5, 132.1, 130.3, 128.3, 127.4, 127.3, 126.4, 126.2, 125.8, 113.2, 48.1, 25.8, 20.0; HRMS (ESI+): Calcd for C₁₉H₂₁ [M+H]⁺: 249.1643, Found: 249.1643. Optical Rotation: $[\alpha]_D^{20}$ –29.53 (*c* 1.63, CHCl₃) for an enantiomerically enriched sample of 95:5 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (95.9:4.1 er shown; Chiralcel OD-H column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



|--|

(*R*,*E*)-1-Methoxy-4-(3-methyl-3-phenylpenta-1,4-dien-1-yl)benzene (entry 3, Table 2). IR (neat): 3082 (w), 3056 (w), 3030 (w), 3021 (w), 2970 (w), 2933 (w), 2835 (w), 1607 (m), 1510 (s), 1443 (w), 1280 (w), 1246 (s), 1174 (m), 1034 (m), 972 (w), 917 (w), 808 (w), 762 (m), 700 (m), 533 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.39–7.30 (6H, m), 7.22 (1H, tt, *J* = 6.4, 2.0 Hz), 6.88–6.84 (2H, m), 6.33 (2H, s), 6.17 (1H, dd, *J* = 17.6, 10.4 Hz), 5.18 (1H, dd, *J* = 10.4, 1.2 Hz), 5.07 (1H, dd, *J* = 17.2, 1.2 Hz), 3.81 (3H, s), 1.60 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 159.1, 146.7, 145.4, 135.2, 130.4, 128.3, 127.6, 127.5, 127.4, 126.3, 114.1, 113.0, 55.5, 47.9, 25.8; HRMS (ESI+): Calcd for C₁₉H₂₁O₁ [M+H]⁺: 265.1592, Found: 265.1590. Optical Rotation: [α]_D²⁰ +24.49 (*c* 1.16, CHCl₃) for an enantiomerically enriched sample of 96.5:3.5 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (95.9:4.1 er shown; Chiralcel OD-H column, 97/3 hexanes/*i*-PrOH, 1.0 mL/min, 254 nm).



Peak#	Ret. Time	Area%	Peak#	Ret. Time	Area%
1	26.58	50.4	1	26.73	95.9
2	33.18	49.6	2	33.92	4.1

(*R*,*E*)-1-(3-Methyl-3-phenylpenta-1,4-dien-1-yl)-4-(trifluoromethyl)benzene (entry 4, Table 2). IR (neat): 2924 (m), 2854 (w), 1615 (w), 1323 (s), 1165 (m), 1125 (s), 1067 (s), 1016 (w), 975 (w), 919 (w), 815 (w), 762 (w), 699 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.56 (2H, d, *J* = 8.4 Hz), 7.48 (2H, d, *J* = 8.4 Hz), 7.38–7.32 (4H, m), 7.27–7.22 (1H, m), 6.57 (1H, d, *J* = 16.0 Hz), 6.40 (1H, d, *J* = 16.0 Hz), 6.17 (1H, dd, *J* = 17.6, 10.4 Hz), 5.22 (1H, dd, *J* = 10.8, 1.2 Hz), 5.09 (1H, dd, *J* = 17.6, 1.2 Hz), 1.63 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 146.0, 144.8 (q, *J* = 5.2 Hz), 141.2 (q, *J* = 1.5 Hz), 140.0 (q, *J* = 3.0 Hz), 132.1, 129.2 (q, *J* = 32.0 Hz), 128.5, 127.3, 127.1 (q, *J* = 3.8 Hz), 126.6 (q, *J* = 4.5 Hz), 125.7 (q, *J* = 10.4 Hz), 124.4 (q, *J* = 270.0 Hz), 113.6 (q, *J* = 3.0 Hz), 48.1, 25.6; HRMS (ESI+): Calcd for C₁₉H₁₈F₃ [M+H]⁺: 303.1361, Found: 303.1373. Optical Rotation: [α]_D²⁰ –26.78 (*c* 2.47, CHCl₃) for an enantiomerically enriched sample of 94:6 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (94.0:6.0 er shown; Chiralcel OD-H column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*E*)-1-(3-Methyl-1-phenylpenta-1,4-dien-3-yl)-2-nitrobenzene (entry 6, Table 2). IR (neat): 3082 (w), 3026 (w), 2925 (w), 2854 (w), 1528 (s), 1366 (s), 971 (m), 909 (s), 852 (m), 777 (m), 731 (s), 692 (s), 649 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.59 (1H, dd, *J* = 8.0, 1.2 Hz), 7.50–7.46 (2H, m), 7.38–7.29 (5H, m), 7.23 (1H, tt, *J* = 6.4, 1.6 Hz), 6.40 (1H, d, *J* = 16.4 Hz), 6.35 (1H, d, *J* = 16.4 Hz), 6.10 (1H, dd, *J* = 17.6, 10.4 Hz), 5.18 (1H, d, *J* = 10.8 Hz), 5.13 (1H, d, *J* = 17.6 Hz), 1.79 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 151.4, 142.7, 138.8, 137.2, 134.8, 131.4, 130.4, 128.8, 128.7, 127.8, 127.6, 126.5, 124.5, 113.8, 47.7, 25.6; HRMS (ESI+): Calcd for C₁₈H₁₈N₁O₂ [M+H]⁺: 280.1338, Found: 280.1327. Optical Rotation: $[\alpha]_D^{20}$ –23.19 (*c* 1.71, CHCl₃) for an enantiomerically enriched sample of 98:2 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (97.8:2.2 er shown; Chiralcel OD-H column, 99.5/0.5 hexanes/*i*-PrOH, 0.5 mL/min, 220 nm).



Peak#	Ret. Time	Area%	Peak#	Ret. Time	Area%
1	23.69	49.7	1	25.86	2.2
2	24.99	50.3	2	28.89	97.8

(*R*,*E*)-1-(1-(4-Methoxyphenyl)-3-methylpenta-1,4-dien-3-yl)-2-methylbenzene (entry 7, **Table 2).** IR (neat): 3000 (w), 2968 (w), 2932 (w), 2835 (w), 1607 (m), 1510 (s), 1248 (s), 1175 (m), 1036 (m), 972 (w), 915 (w), 815 (w), 759 (w), 730 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.42–7.40 (1H, m), 7.29–7.25 (2H, m), 7.19–7.13 (3H, m), 6.85–6.80 (2H, m), 6.38 (1H, d, *J* = 16.0 Hz), 6.25–6.15 (2H, m), 5.11 (1H, dd, *J* = 10.8, 1.2 Hz), 4.95 (1H, dd, *J* = 17.2, 1.2 Hz), 3.80 (3H, s), 2.33 (3H, s), 1.62 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 158.8, 145.4, 144.1, 137.4, 135.5, 132.3, 130.5, 127.5, 127.2, 126.9, 126.5, 125.6, 113.9, 112.3, 55.3, 48.2, 27.0, 22.6; HRMS (ESI+): Calcd for C₂₀H₂₁O₁ [M+H]⁺: 277.1592, Found: 277.1598. Optical Rotation: [α]_D²⁰ –14.23 (*c* 1.07, CHCl₃) for an enantiomerically enriched sample of 98:2 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (98.1:1.9 er shown; Chiralcel OJ-H column, 95/5 hexanes/*i*-PrOH, 1.0 mL/min, 254 nm).



(*R*,*E*)-1-(3-Methyl-1-phenylpenta-1,4-dien-3-yl)-4-nitrobenzene (entry 8, Table 2). IR (neat): 3082 (w), 3026 (w), 2974 (w), 2931 (w), 2852 (w), 1596 (m), 1514 (s), 1343 (s), 1111 (w), 1068 (w), 971 (m), 919 (m), 852 (s), 748 (s), 735 (s), 692 (s), 613 (w), 537 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.19–8.15 (2H, m), 7.55–7.52 (2H, m), 7.40–7.37 (2H, m), 7.34–7.31 (2H, m), 7.27–7.25 (1H, m), 6.44–6.35 (2H, m), 6.14 (1H, dd, *J* = 17.6, 10.8 Hz), 5.27 (1H, dd, *J* = 10.4, 0.8 Hz), 5.10 (1H, dd, *J* = 17.6, 0.8 Hz), 1.64 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 154.2, 146.6, 143.8, 137.0, 135.5, 129.5, 128.8, 128.4, 127.8, 126.5, 123.6, 114.5, 48.3, 25.8; HRMS

(ESI+): Calcd for $C_{18}H_{18}N_1O_2$ [M+H]⁺: 280.1338, Found: 280.1339. Optical Rotation: $[\alpha]_D^{20}$ – 20.37 (*c* 2.42, CHCl₃) for an enantiomerically enriched sample of 93:7 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (93.7:6.3 er shown; Chiralcel OJ-H column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 254 nm).



Peak#	Ret. Time	Area%	Peak#	Ret. Time	Area%
1	49.71	49.2	1	47.06	6.7
2	53.53	50.8	2	49.49	93.3

(*R*,*E*)-1-Methoxy-4-(3-methyl-3-(4-(trifluoromethyl)phenyl)penta-1,4-dien-1-yl)benzene (entry 9, Table 2). IR (neat): 2957 (w), 2926 (w), 2854 (w), 1608 (w), 1511 (m), 1326 (s), 1248 (m), 1165 (m), 1123 (s), 1076 (m), 1036 (w), 1016 (w), 973 (w), 921 (w), 841 (m) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.56 (2H, d, *J* = 8.0 Hz), 7.48 (2H, d, *J* = 8.0 Hz), 7.34–7.30 (2H, m), 6.87–6.84 (2H, m), 6.32 (1H, d, *J* = 16.4 Hz), 6.26 (1H, d, *J* = 16.4 Hz), 6.13 (1H, dd, *J* = 17.2, 10.4 Hz), 5.22 (1H, dd, *J* = 10.8, 1.2 Hz), 5.07 (1H, dd, *J* = 17.6, 1.2 Hz), 3.81 (3H, s), 1.60 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 159.3, 150.9, 144.6, 134.2, 130.1, 128.6 (q, *J* = 32.0 Hz), 128.4, 127.8, 127.6, 125.2 (q, *J* = 3.7 Hz), 124.4 (q, *J* = 270.1 Hz), 114.2, 113.8, 55.5, 48.0, 25.8; HRMS (ESI+): Calcd for C₂₀H₂₀F₃O₁ [M+H]⁺: 333.1466, Found: 333.1480. Optical Rotation: $[\alpha]_D^{20}$ –22.91 (*c* 1.11, CHCl₃) for an enantiomerically enriched sample of 94:6 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (94.0:6.0 er shown; Chiralcel OD-H column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*E*)-(3,7-Dimethyl-3-vinylocta-1,6-dien-1-yl)benzene (entry 10, Table 2). IR (neat): 3082 (w), 3059 (w), 3026 (w), 2966 (w), 2915 (w), 2854 (w), 1633 (w), 1598 (w), 1492 (w), 1447 (w), 1374 (w), 968 (m), 912 (m), 831 (w), 745 (s), 691 (s) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.39–7.37 (2H, m), 7.33–7.29 (2H, m), 7.21 (1H, tt, *J* = 6.4, 1.6 Hz), 6.34 (1H, d, *J* = 16.8 Hz), 6.22 (1H, d, *J* = 16.0 Hz), 5.91 (1H, dd, *J* = 17.2, 10.8 Hz), 5.15–5.11 (1H, m), 5.08–5.02 (2H, m), 1.98 (2H, dt, *J* = 7.6, 7.6 Hz), 1.69 (3H, s), 1.60 (3H, s), 1.55–1.50 (2H, m), 1.23 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 145.9, 138.05, 138.03, 131.5, 128.6, 127.4, 127.1, 126.2, 124.9, 112.2, 42.8, 41.4, 25.8, 23.5, 23.4, 17.8; HRMS (ESI+): Calcd for C₁₈H₂₅ [M+H]⁺: 241.1956, Found: 241.1945. Optical Rotation: [α]_D²⁰ +23.80 (*c* 1.83, CHCl₃) for an enantiomerically enriched sample of 90:10 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (89.9:10.1 er shown; Chiralcel OD-H column, 95/5 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



	2	15.42	50.4	2	15.60	10.1
--	---	-------	------	---	-------	------

(*R*,*E*)-1-(3,7-Dimethyl-3-vinylocta-1,6-dien-1-yl)-2-methylbenzene (entry 11, Table 2). Spectra are taken in the presence of 14% alkynyl adduct. IR (neat): 3019 (w), 2967 (m), 2921 (m), 2856 (w), 1636 (w), 1602 (w), 1511 (w), 1484 (w), 1457 (m), 1376 (w), 1248 (w), 1036 (w), 972 (m), 914 (m), 748 (s) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.43–7.40 (1H, m), 7.20–7.11 (3H, m), 6.53 (1H, d, J = 16.4 Hz), 6.07 (1H, d, J = 16.4 Hz), 5.92 (1H, dd, J = 17.6, 10.8 Hz), 5.16–5.10 (1H, m), 5.08–5.02 (2H, m), 2.34 (3H, s), 1.98 (2H, dt, J = 7.6, 7.6 Hz), 1.69 (3H, s), 1.60 (3H, s), 1.53–1.50 (2H, m), 1.23 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 146.0, 143.6, 139.6, 137.4, 135.3, 132.1, 131.5, 130.2, 127.0, 126.2, 124.9, 112.2, 43.0, 42.4, 41.4, 25.8, 23.7, 23.4, 17.8; HRMS (ESI+): Calcd for C₁₉H₂₇ [M+H]⁺: 255.2113, Found: 255.2115. Optical Rotation: [α]_D²⁰ –23.46 (*c* 1.02, CHCl₃) for an enantiomerically enriched sample of 91:9 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (91.0:9.0 er shown; Chiralcel OD-H column, 99/1 hexanes/*i*-PrOH, 1.0 mL/min, 220 nm).



(*R*,*E*)-1-(3,7-Dimethyl-3-vinylocta-1,6-dien-1-yl)-4-methoxybenzene (entry 12, Table 2). IR (neat): 2965 (m), 2916 (m), 1608 (m), 1510 (s), 1456 (w), 1280 (s), 1247 (m), 1037 (m), 970 (w), 913 (w), 815 (w), 527 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.31–7.29 (2H, m), 6.86–6.84 (2H, m), 6.27 (1H, d, *J* = 16.4 Hz), 6.07 (1H, d, *J* = 16.4 Hz), 5.89 (1H, dd, *J* = 17.2, 10.8 Hz), 5.14–5.10 (1H, m), 5.06–5.00 (2H, m), 3.81 (3H, s), 1.96 (2H, dt, *J* = 7.6, 7.6 Hz), 1.68 (3H, s), 1.59 (3H, s), 1.53–1.48 (2H, m), 1.21 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 158.9, 146.2, 136.0, 131.4, 130.9, 127.3, 126.7, 124.9, 114.1, 112.0, 55.5, 42.7, 41.5, 25.8, 23.5, 23.4, 17.8; HRMS (ESI+): Calcd for C₁₉H₂₇O₁ [M+H]⁺: 271.2062, Found: 271.2064. Optical Rotation: [α]_D²⁰ –25.16 (*c* 1.91, CHCl₃) for an enantiomerically enriched sample of 91:9 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in

comparison with authentic racemic material (90.4:9.6 er shown; Chiralcel OD-H column, 97/3 hexanes/*i*-PrOH, 0.8 mL/min, 220 nm).



(*R*,*E*)-1-(3,7-Dimethyl-3-vinylocta-1,6-dien-1-yl)-4-(trifluoromethyl)benzene (entry 13, **Table 2).** IR (neat): 2969 (w), 2919 (w), 1616 (w), 1453 (w), 1413 (w), 1376 (w), 1323 (s), 1164 (m), 1124 (s), 1067 (m), 1016 (w), 973 (w), 916 (w), 817 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.54 (2H, d, *J* = 8.4 Hz), 7.44 (2H, d, *J* = 8.4 Hz), 6.36 (1H, d, *J* = 16.0 Hz), 6.30 (1H, d, *J* = 16.0 Hz), 5.89 (1H, ddd, *J* = 17.2, 10.4, 0.8 Hz), 5.12–5.06 (2H, m), 5.03 (1H, dd, *J* = 17.2, 1.2 Hz), 1.96 (2H, dt, *J* = 7.2, 7.2 Hz), 1.68 (3H, s), 1.58 (3H, s), 1.55–1.50 (2H, m), 1.23 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 145.4, 141.5 (q, *J* = 1.4 Hz), 140.9, 131.7, 128.9 (q, *J* = 32.0 Hz), 126.4, 126.2, 125.6 (q, *J* = 3.7 Hz), 124.7, 124.4 (q, *J* = 270.1 Hz), 112.6, 43.0, 41.3, 25.8, 23.4, 23.3, 17.8; HRMS (ESI+): Calcd for C₁₉H₂₄F₃ [M+H]⁺: 309.1830, Found: 309.1830. Optical Rotation: [α]_D²⁰ +13.68 (*c* 1.41, CHCl₃) for an enantiomerically enriched sample of 87:13 er.

Enantiomeric purity is determined by HPLC analysis of the derived primary alcohol (obtained from hydroboration of the terminal olefin with 9-BBN, followed by oxidation with H_2O_2) in comparison with authentic racemic material (87.2:12.8 er shown; Chiralcel OJ-H column, 99/1 hexanes/*i*-PrOH, 0.5 mL/min, 220 nm).



1	36.02	49.4	1	36.06	12.8
2	40.64	50.6	2	39.92	87.2

v Enantioselective Synthesis of R-(–)-bakuchiol (Scheme 7): Procedure for Demethylation of Bakuchiol Methyl Ether (Compound in entry 12, Table 2). A flame-dried 6-dram vial is charged with bakuchiol methyl ether (21.4 mg, 0.079 mmol) and a stir bar. The vial is sealed with a septum and purged with N₂ flow for 10 minutes. Freshly prepared MeMgI in diethyl ether (990 µL, 0.396 mmol) is added to the reaction vessel and solvent is carefully removed under reduced pressure. The resulting mixture is heated in a 180 °C oil bath for 10 minutes (white smoke generated as the reaction goes on and disappears in 10 minutes), after which time, it is allowed to cool to 22 °C and diluted with Et₂O (5 mL). A saturated solution of NH₄Cl is added to quench the reaction and layers are separated. The aqueous layer is washed with Et₂O (5 mL x 3) and the combined organic layers are dried with anhydrous MgSO₄, filtered and concentrated in vacuo to afford a slightly yellow oil, which is subjected to silica gel chromatography (10:1 hexanes:ethyl acetate) to furnish the desired product as colorless oil (16.4 mg, 0.064 mmol, 81% yield). R-(-)-Bakuchiol. IR (neat): 3345 (br), 2966 (m), 2919 (m), 2862 (w), 1609 (m), 1511 (s), 1441 (m), 1374 (w), 1235 (m), 1171 (m), 970 (m), 914 (m), 813 (w), 527 (w) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.27–7.24 (2H, m), 6.79–6.76 (2H, m), 6.25 (1H, d, J = 16.0 Hz), 6.06 (1H, d, J = 16.0 Hz), 5.88 (1H, dd, J = 17.2, 10.8 Hz), 5.13-5.09 (1H, m), 5.05-4.99 (2H, m),4.74 (1H, br), 1.96 (2H, dt, J = 7.6, 7.6 Hz), 1.68 (3H, s), 1.58 (3H, s), 1.52–1.47 (2H, m), 1.20 (3H, s); ¹³C NMR (100 MHz, CDCl₃): δ 154.8, 146.1, 136.0, 131.5, 131.1, 127.5, 126.6, 125.0, 115.5, 112.0, 42.7, 41.4, 25.8, 23.5, 23.4, 17.8; HRMS (ESI+): Calcd for C₁₈H₂₅O₁ [M+H]⁺: 257.1905, Found: 257.1903. Optical Rotation: $[\alpha]_D^{20}$ –23.81 (*c* 1.14, CHCl₃) for an enantiomerically enriched sample of 91:9 er.

v Correlation of Stereochemistry: The stereochemical identity of bakuchiol derived from bakuchiol methyl ether in entry 12, Table 2 is determined to be R-(–)-bakuchiol by comparison with the data previously reported.¹⁰ All the compounds generated in this study therefore are assigned as the *R* enantiomer by inference through analogy with bakuchiol methyl ether in entry 12, Table 2.



Scheme S1. Demethylation of R-(---)-Bakuchiol Methyl Ether and Stereochemistry Proof

⁽¹⁰⁾ Du, X-L.; Chen, H-L.; Feng, H-J.; Li, Y-C. Helv. Chim. Acta 2008, 91, 371-378.